SMS Pharmaceuticals cash flow

Latest FY26

Cash from operations: ₹59.2cr−27.5% on FY25
Capital spending: ₹131cr+5.8% on FY25
Free cash flow: −₹71.3cr−₹41.7 cr in FY25
Cash from financing: ₹76.0cr+61.5% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	39.9	34.3	31.5	32.1
	—	21.8	17.4	22.5	21.1
	—	−0.6	−0.2	−0.2	−0.1
	—	0.5	−1.0	0.0	−0.2
	—	0.1	−0.2	−0.0	0.0
	—	0.0	−0.0	−0.0	0.1
	—	0.0	0.0	0.2	0.0
	—	−66.5	−51.0	−10.2	27.6
	—	−12.6	33.0	−87.8	−99.8
	—	6.3	−6.6	3.3	−3.8
	—	−0.3	−1.8	−0.1	−0.1
	—	−7.6	9.6	0.5	8.0
	—	−22.3	4.9	−8.3	−1.3
	—	6.5	−37.4	43.9	40.3
	—	1.3	6.2	2.2	0.0
	—	1.2	−0.0	1.9	−2.2
	—	0.0	0.0	0.0	−0.3
Cash from operating activities
	119	117	92.3	66.1	5.3
	—	−33.3	9.2	−0.6	21.7
	—	83.3	102	65.5	27.1
	—	24.1	19.8	15.4	4.6
	—	59.2	81.7	50.1	22.5
Cash from investing activities
	—	131	123	52.2	29.9
	—	0.0	0.1	0.1	0.3
	—	0.0	0.0	0.0	0.1
	—	0.8	0.2	0.2	0.2
	—	−1.0	−0.3	−0.2	−0.1
	—	−131	−123	−52.1	−29.7
Cash from financing activities
	—	47.6	38.1	28.5	0.0
	—	88.4	63.7	45.1	35.3
	—	34.4	44.1	37.8	43.1
	—	0.0	0.7	1.0	0.7
	—	22.1	17.4	21.8	20.9
	—	3.5	3.4	2.5	2.5
	—	0.0	10.8	20.2	0.0
	—	76.0	47.1	30.7	−32.0
	—	4.5	5.4	28.7	−39.2
	—	4.5	5.4	28.7	−39.2
	—	—	—	36.0	7.4
Reference items
	173	171	139	117	54.5
	19.3%	19.3%	17.8%	16.4%	10.4%
	−71.3	−71.3	−41.7	−2.0	−7.5
	—	−39.2	−28.4	3.9	—
	−₹7.62	−₹7.62	−₹4.45	−₹0.22	−₹0.80
	—	0.58×	1.18×	1.01×	−3.18×
	—	24.1	19.8	15.4	4.6
	—	22.1	17.4	21.8	20.9

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SMSPHARMA₹475.45

SMS Pharmaceuticals Limited

· Pharma & Health

₹ CrorePeersINDSWFTLAB SOLARA DCAL UNICHEMLAB GUFICBIO RPGLIFE HIKAL GUJTHEMMcap ₹4,453 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	32.1	31.5	34.3	39.9	—
+ Finance Costs	21.1	22.5	17.4	21.8	—
+ Interest Income	-0.1	-0.2	-0.2	-0.6	—
+ Undistributed Profits of Associates	-0.2	0.0	-1.0	0.5	—
+ Other Non-cash Items	0.0	-0.0	-0.2	0.1	—
+ Other — Cash Effects are Investing / Financing	0.1	-0.0	-0.0	0.0	—
+ Other Reconciling Items	0.0	0.2	0.0	0.0	—
Changes in Working Capital
+ Inventories	27.6	-10.2	-51.0	-66.5	—
+ Trade Receivables — Current	-99.8	-87.8	33.0	-12.6	—
+ Other Financial Assets — Current	-3.8	3.3	-6.6	6.3	—
+ Other Financial Assets — Non-current	-0.1	-0.1	-1.8	-0.3	—
+ Other Current Assets	8.0	0.5	9.6	-7.6	—
+ Other Non-current Assets	-1.3	-8.3	4.9	-22.3	—
+ Trade Payables — Current	40.3	43.9	-37.4	6.5	—
+ Other Financial Liabilities — Current	0.0	2.2	6.2	1.3	—
+ Other Current Liabilities	-2.2	1.9	-0.0	1.2	—
+ Provisions — Current	-0.3	0.0	0.0	0.0	—
Cash from Operating Activities
Profit Before Tax (per I/S)	5.3	66.1	92.3	116.6	119.5
+ Total Adjustments (incl. Working Capital)	21.7	-0.6	9.2	-33.3	—
Cash from Operations (pre-tax)	27.1	65.5	101.5	83.3	—
+ Income Taxes Paid	4.6	15.4	19.8	24.1	—
Cash from Operating Activities	22.5	50.1	81.7	59.2	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	29.9	52.2	123.4	130.6	—
+ Disp of Fixed Assets	0.3	0.1	0.1	0.0	—
+ Acq of Investment Property	0.1	0.0	0.0	0.0	—
+ Interest Received — Investing	0.2	0.2	0.2	0.8	—
+ Other Inflows / (Outflows) — Investing	-0.1	-0.2	-0.3	-1.0	—
Cash from Investing Activities	-29.7	-52.1	-123.4	-130.8	—
Cash from Financing Activities
+ Proceeds from Other Equity Instruments	0.0	28.5	38.1	47.6	—
+ Proceeds from Borrowings	35.3	45.1	63.7	88.4	—
+ Repayment of Borrowings	43.1	37.8	44.1	34.4	—
+ Payment of Lease Liabilities	0.7	1.0	0.7	0.0	—
+ Interest Paid	20.9	21.8	17.4	22.1	—
+ Dividends Paid	2.5	2.5	3.4	3.5	—
+ Other Inflows / (Outflows) — Financing	0.0	20.2	10.8	0.0	—
Cash from Financing Activities	-32.0	30.7	47.1	76.0	—
Net Changes in Cash (pre-FX)	-39.2	28.7	5.4	4.5	—
Net Changes in Cash	-39.2	28.7	5.4	4.5	—
Closing Cash	7.4	36.0	—	—	—
Reference Items
EBITDA	54.5	116.6	139.0	171.3	172.9
EBITDA Margin %	10.44	16.44	17.76	19.31	19.25
Free Cash Flow (CFO − Capex)	-7.5	-2.0	-41.7	-71.3	-71.3
Free Cash Flow to Equity	—	3.9	-28.4	-39.2	—
Free Cash Flow per Basic Share	-0.80	-0.22	-4.45	-7.62	-7.62
Cash Flow to Net Income	-3.18	1.01	1.18	0.58	—
Cash Paid for Taxes	4.6	15.4	19.8	24.1	—
Cash Paid for Interest	20.9	21.8	17.4	22.1	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.